Covid-19 vaccine by US pharma giant Pfizer shows promising results in early trials

Prashasti Awasthi Mumbai | Updated on August 15, 2020

A sign is pictured outside Pfizer Headquarters in the Manhattan borough of New York City   -  REUTERS

The early trials of the Covid-19 vaccine that is being developed by the pharmaceutical giant Pfizer have shown promising and safe results.

The results of phase I and II clinical trials were published in Nature and the journal of Science Board.

Pfizer is using the technique that will fight the virus by alerting messenger RNA to elicit immune responses.


According to the report, RNA vaccines provide flexibility in the design and expression of vaccine antigens. The RNA can imitate antigen structures and expression during natural infection.

Moreover, they are considered safe because RNA is only transiently expressed and metabolized. These can subsequently be eliminated by natural mechanisms.

The Bnt162b1 vaccine candidate, developed by Pfizer and BioNTech, incorporates nucleoside-modified RNA, that is required for the production of large amounts of antigen and for robust immune responses.

It also encodes the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, a key target of virus-neutralizing antibodies.

The researchers stated that the vaccine is safe with only mild side effects that appear with the increased dosage seven days post-vaccination.

United States administration has already secured access to 300 million doses of the experimental vaccine which will likely arrive in early 2021.

Published on August 15, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor